Thrombocytopenia and nausea were the most common hematological and non-hematological adverse events, respectively.<h4>Conclusion</h4>This meta-analysis demonstrated that HDAC inhibitors were effective treatment options for untreated and R/R PTCL patients. The gene discussed is HDAC9; the disease is Thrombocytopenia.